Journal of IiMER Volume 10 Issue 1 comprehensive understanding of the compromised physiology in ME/CFS relating to this post exercise malaise. ME/CFS lends itself to longitudinal intensive molecular study to understand fluctuating health through relapse and recovery and steady state health periods, just as the Snyder study described above monitored molecular changes through compromised health episodes with viral illnesses. The precision medicine approach can be used to analyse what is happening in individual ME/CFS patients, and determine whether there are common mechanisms behind the relapses in each member of a small cohort of patients. Additionally, pregnancy in some women ME/CFS patients can lead to a significant alleviation in symptoms, perhaps because of increased blood suppression volume, of allergic responses, and their changed hormonal profile. Understanding what dysregulated pathways are reversed in this situation through molecular analysis may give further insight into the nature of ME/CFS. Additionally, new technology is now available that can assess mitochondrial functions in isolated blood cells and that may be additional information that can be added. We work towards a goal of providing a diagnosis that combines multiple molecular biomarkers linked to References 1) Welcome to ANZMES. The Associated New Zealand ME Society Inc, Auckland, New Zealand. http://www.anzmes.org.nz 2) Newman SK, Jayanthan RK, Mitchell GW, Carreras Tartak JA, Croqlio MP, Suarez A, Liu AY, Razzo BM, Oveniran E, Ruth JR, Fajgenbaum DC (2015) Taking Control of Castleman Disease: Leveraging Precision Medicine Technologies to Accelerate Rare Invest in ME (Charity Nr. 1114035) www.investinme.org Disease Page 53 of 77 June 2016 dysregulated biologically plausible pathways, and understanding the compromised physiology and can lead to more effective treatments for the heterogeneous symptomology of the ME/CFS patient group, not only aiding clinicians in choosing treatment options, but perhaps also helping in the stratification of patients in clinical trials. Acknowledgements: We are grateful for support from ANZMES the national ME/CFS group of New Zealand, Lottery Health Fund of New Zealand, H S and J C Anderson Charitable Trust, a private bequest.

54 Publizr Home

You need flash player to view this online publication